Related Experiment Video

Updated: Mar 10, 2026

Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

7.3K

New targeted therapies for malignant lymphoma based on molecular heterogeneity

Heike Horn1, Annette M Staiger1,2, German Ott2

  • 1a Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart and University of Tübingen , Stuttgart , Germany.

Expert Review of Hematology
|December 6, 2016
PubMed
Abstract

Insights

Novel targeted drugs are revolutionizing cancer treatment, especially for malignant lymphomas. Research is exploring tailored therapies like monoclonal antibodies and effector molecule inhibitors for B-cell lymphomas (B-NHL).

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Advances in understanding tumor pathogenesis have spurred the development of targeted drugs.
  • Malignant lymphomas are a heterogeneous group with diverse clinical outcomes.
  • Molecular profiling of tumors has enabled the creation of new targeted therapies.

Purpose of the Study:

  • To review current tailored therapeutic approaches for malignant lymphomas, particularly B-cell lymphomas (B-NHL).
  • To summarize preclinical and clinical trial data on novel targeted therapies in B-NHL.

Main Methods:

  • Literature review of targeted therapies in B-cell lymphomas.
  • Analysis of preclinical studies and clinical trials for B-NHL treatments.
  • Focus on monoclonal antibodies and effector molecule inhibition.

Main Results:

  • Targeted therapies, including monoclonal antibodies and effector molecule inhibitors, are under investigation for B-NHL.
  • These approaches show promise in various B-NHL subtypes.
  • Ongoing preclinical and clinical studies are evaluating their efficacy.

Conclusions:

  • Tailored therapeutic strategies for B-NHL are rapidly advancing.
  • The translation of basic science discoveries into clinical applications is promising for future lymphoma treatments.
Keywords:
ABC-like DLBCLB-cell Non-Hodgkin lymphoma (B-NHL)GCB-like DLBCLdiffuse large B-cell lymphoma (DLBCL)immune modulatory drugsmonoclonal antibodiesproteasome inhibitorssmall molecule inhibitorstyrosine kinase inhibitors

More Related Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.7K
Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

2.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
55.3K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
60